Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis.

Sohn WY, Portale AA, Salusky IB, Zhang H, Yan LL, Ertik B, Shahinfar S, Lee E, Dehmel B, Warady BA.

Pediatr Nephrol. 2018 Dec 7. doi: 10.1007/s00467-018-4154-5. [Epub ahead of print]

PMID:
30536181
2.

Non-renal-Related Mechanisms of FGF23 Pathophysiology.

Hanudel MR, Laster M, Salusky IB.

Curr Osteoporos Rep. 2018 Dec;16(6):724-729. doi: 10.1007/s11914-018-0492-2. Review.

PMID:
30353318
3.

Impaired osteocyte maturation in the pathogenesis of renal osteodystrophy.

Pereira RC, Salusky IB, Roschger P, Klaushofer K, Yadin O, Freymiller EG, Bowen R, Delany AM, Fratzl-Zelman N, Wesseling-Perry K.

Kidney Int. 2018 Nov;94(5):1002-1012. doi: 10.1016/j.kint.2018.08.011.

PMID:
30348285
4.

Racial-ethnic differences in chronic kidney disease-mineral bone disorder in youth on dialysis.

Laster M, Soohoo M, Streja E, Elashoff R, Jernigan S, Langman CB, Norris KC, Salusky IB, Kalantar-Zadeh K.

Pediatr Nephrol. 2019 Jan;34(1):107-115. doi: 10.1007/s00467-018-4048-6. Epub 2018 Sep 29.

PMID:
30267239
5.

An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis.

Sohn WY, Portale AA, Salusky IB, Zhang H, Yan LL, Ertik B, Shahinfar S, Lee E, Dehmel B, Warady BA.

Pediatr Nephrol. 2019 Jan;34(1):145-154. doi: 10.1007/s00467-018-4054-8. Epub 2018 Aug 23. Erratum in: Pediatr Nephrol. 2018 Dec 7;:.

6.

Effects of erythropoietin on fibroblast growth factor 23 in mice and humans.

Hanudel MR, Eisenga MF, Rappaport M, Chua K, Qiao B, Jung G, Gabayan V, Gales B, Ramos G, de Jong MA, van Zanden JJ, de Borst MH, Bakker SJL, Nemeth E, Salusky IB, Gaillard CAJM, Ganz T.

Nephrol Dial Transplant. 2018 Jul 10. doi: 10.1093/ndt/gfy189. [Epub ahead of print]

PMID:
30007314
7.

Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients.

Hanudel MR, Laster M, Ramos G, Gales B, Salusky IB.

Pediatr Nephrol. 2018 Nov;33(11):2137-2142. doi: 10.1007/s00467-018-3999-y. Epub 2018 Jun 28.

PMID:
29956006
8.

Skeletal Consequences of Nephropathic Cystinosis.

Florenzano P, Ferreira C, Nesterova G, Roberts MS, Tella SH, de Castro LF, Brown SM, Whitaker A, Pereira RC, Bulas D, Gafni RI, Salusky IB, Gahl WA, Collins MT.

J Bone Miner Res. 2018 Oct;33(10):1870-1880. doi: 10.1002/jbmr.3522. Epub 2018 Jul 20.

PMID:
29905968
9.

Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease.

Hanudel MR, Rappaport M, Chua K, Gabayan V, Qiao B, Jung G, Salusky IB, Ganz T, Nemeth E.

Haematologica. 2018 Apr;103(4):e141-e142. doi: 10.3324/haematol.2017.181743. Epub 2018 Feb 1. No abstract available.

10.

Erratum to "Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease" [Bone, 45(6) (2009) 1161-1168].

Pereira RC, Jűppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K.

Bone. 2018 Mar;108:210-211. doi: 10.1016/j.bone.2017.12.019. Epub 2017 Dec 28. No abstract available.

PMID:
29290423
11.

FGF23 and Left Ventricular Hypertrophy in Children with CKD.

Mitsnefes MM, Betoko A, Schneider MF, Salusky IB, Wolf MS, Jüppner H, Warady BA, Furth SL, Portale AA.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):45-52. doi: 10.2215/CJN.02110217. Epub 2017 Oct 12.

12.

Development of a translational research pathway at the David Geffen School of Medicine University of California, Los Angeles.

Demyan L, Harview C, Miller E, Wilkerson L, Salusky IB.

Int J Med Educ. 2017 Sep 22;8:334-335. doi: 10.5116/ijme.59ae.c221. No abstract available.

13.

Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow.

Clinkenbeard EL, Hanudel MR, Stayrook KR, Appaiah HN, Farrow EG, Cass TA, Summers LJ, Ip CS, Hum JM, Thomas JC, Ivan M, Richine BM, Chan RJ, Clemens TL, Schipani E, Sabbagh Y, Xu L, Srour EF, Alvarez MB, Kacena MA, Salusky IB, Ganz T, Nemeth E, White KE.

Haematologica. 2017 Nov;102(11):e427-e430. doi: 10.3324/haematol.2017.167882. Epub 2017 Aug 17. No abstract available.

14.

Fractures and Osteomalacia in a Patient Treated With Frequent Home Hemodialysis.

Hanudel MR, Froch L, Gales B, Jüppner H, Salusky IB.

Am J Kidney Dis. 2017 Sep;70(3):445-448. doi: 10.1053/j.ajkd.2017.03.015. Epub 2017 May 9.

15.

Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder.

Hanudel MR, Salusky IB.

Curr Osteoporos Rep. 2017 Jun;15(3):198-206. doi: 10.1007/s11914-017-0365-0. Review.

16.

Increased serum hepcidin contributes to the anemia of chronic kidney disease in a murine model.

Hanudel MR, Rappaport M, Gabayan V, Jung G, Salusky IB, Nemeth E, Ganz T, Zaritsky J.

Haematologica. 2017 Mar;102(3):e85-e88. doi: 10.3324/haematol.2016.150433. Epub 2016 Nov 24. No abstract available.

17.

Racial-ethnic disparities in mortality and kidney transplant outcomes among pediatric dialysis patients.

Laster M, Soohoo M, Hall C, Streja E, Rhee CM, Ravel VA, Reddy U, Norris KC, Salusky IB, Kalantar-Zadeh K.

Pediatr Nephrol. 2017 Apr;32(4):685-695. doi: 10.1007/s00467-016-3530-2. Epub 2016 Oct 29.

18.

Fibroblast growth factor 23: fueling the fire.

Hanudel M, Jüppner H, Salusky IB.

Kidney Int. 2016 Nov;90(5):928-930. doi: 10.1016/j.kint.2016.08.013.

19.

Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice.

Hanudel MR, Chua K, Rappaport M, Gabayan V, Valore E, Goltzman D, Ganz T, Nemeth E, Salusky IB.

Am J Physiol Renal Physiol. 2016 Dec 1;311(6):F1369-F1377. doi: 10.1152/ajprenal.00281.2016. Epub 2016 Oct 12.

20.

Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.

Portale AA, Wolf MS, Messinger S, Perwad F, Jüppner H, Warady BA, Furth SL, Salusky IB.

Clin J Am Soc Nephrol. 2016 Nov 7;11(11):1989-1998. Epub 2016 Aug 25.

21.

MRI with ferumoxytol: A single center experience of safety across the age spectrum.

Nguyen KL, Yoshida T, Han F, Ayad I, Reemtsen BL, Salusky IB, Satou GM, Hu P, Finn JP.

J Magn Reson Imaging. 2017 Mar;45(3):804-812. doi: 10.1002/jmri.25412. Epub 2016 Aug 2.

22.

Correction: Bone Canopies in Pediatric Renal Osteodystrophy.

Pereira RC, Andersen TL, Friedman PA, Tumber N, Salusky IB, Wesseling-Perry K.

PLoS One. 2016 May 11;11(5):e0155663. doi: 10.1371/journal.pone.0155663. eCollection 2016.

23.

Bone Canopies in Pediatric Renal Osteodystrophy.

Pereira RC, Andersen TL, Friedman PA, Tumber N, Salusky IB, Wesseling-Perry K.

PLoS One. 2016 Apr 5;11(4):e0152871. doi: 10.1371/journal.pone.0152871. eCollection 2016. Erratum in: PLoS One. 2016;11(5):e0155663.

24.

Combining exercise and growth hormone therapy: how can we translate from animal models to chronic kidney disease children?

Bacchetta J, Salusky IB.

Nephrol Dial Transplant. 2016 Aug;31(8):1191-4. doi: 10.1093/ndt/gfv461. Epub 2016 Jan 31. No abstract available.

25.

Micro-CT in the Assessment of Pediatric Renal Osteodystrophy by Bone Histomorphometry.

Pereira RC, Bischoff DS, Yamaguchi D, Salusky IB, Wesseling-Perry K.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):481-7. doi: 10.2215/CJN.04810515. Epub 2015 Dec 28.

26.

Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients.

Hanudel MR, Wesseling-Perry K, Gales B, Ramos G, Campbell V, Ethridge K, Scotti M, Elashoff DA, Alejos J, Reemtsen B, Salusky IB.

Pediatr Nephrol. 2016 Apr;31(4):661-9. doi: 10.1007/s00467-015-3257-5. Epub 2015 Nov 2.

27.

Altered Osteocyte-Specific Protein Expression in Bone after Childhood Solid Organ Transplantation.

Pereira RC, Valta H, Tumber N, Salusky IB, Jalanko H, Mäkitie O, Wesseling Perry K.

PLoS One. 2015 Sep 21;10(9):e0138156. doi: 10.1371/journal.pone.0138156. eCollection 2015.

28.

Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study.

Denburg MR, Kumar J, Jemielita T, Brooks ER, Skversky A, Portale AA, Salusky IB, Warady BA, Furth SL, Leonard MB.

J Am Soc Nephrol. 2016 Feb;27(2):543-50. doi: 10.1681/ASN.2015020152. Epub 2015 Jul 2.

29.

Osteocytic protein expression response to doxercalciferol therapy in pediatric dialysis patients.

Pereira RC, Jüppner H, Gales B, Salusky IB, Wesseling-Perry K.

PLoS One. 2015 Mar 16;10(3):e0120856. doi: 10.1371/journal.pone.0120856. eCollection 2015.

30.

Dr. Ira Greifer.

Kaskel F, Salusky IB.

Pediatr Nephrol. 2015 Apr;30(4):699-700. doi: 10.1007/s00467-014-2985-2. Epub 2015 Jan 27. No abstract available.

PMID:
25620539
31.

Antibacterial responses by peritoneal macrophages are enhanced following vitamin D supplementation.

Bacchetta J, Chun RF, Gales B, Zaritsky JJ, Leroy S, Wesseling-Perry K, Boregaard N, Rastogi A, Salusky IB, Hewison M.

PLoS One. 2014 Dec 30;9(12):e116530. doi: 10.1371/journal.pone.0116530. eCollection 2014.

32.

Primary osteoblast-like cells from patients with end-stage kidney disease reflect gene expression, proliferation, and mineralization characteristics ex vivo.

Pereira RC, Delany AM, Khouzam NM, Bowen RE, Freymiller EG, Salusky IB, Wesseling-Perry K.

Kidney Int. 2015 Mar;87(3):593-601. doi: 10.1038/ki.2014.347. Epub 2014 Oct 29.

33.

High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort.

Nayak AB, Luhar A, Hanudel M, Gales B, Hall TR, Finn JP, Salusky IB, Zaritsky J.

Pediatr Nephrol. 2015 Mar;30(3):515-21. doi: 10.1007/s00467-014-2953-x. Epub 2014 Sep 12.

34.

Cortical and trabecular bone in pediatric end-stage kidney disease.

Carvalho CG, Pereira RC, Gales B, Salusky IB, Wesseling-Perry K.

Pediatr Nephrol. 2015 Mar;30(3):497-502. doi: 10.1007/s00467-014-2942-0. Epub 2014 Sep 4.

35.

The role of bone in CKD-mediated mineral and vascular disease.

Khouzam NM, Wesseling-Perry K, Salusky IB.

Pediatr Nephrol. 2015 Sep;30(9):1379-88. doi: 10.1007/s00467-014-2919-z. Epub 2014 Aug 29. Review.

PMID:
25168424
36.

Lack of FGF23 response to acute changes in serum calcium and PTH in humans.

Wesseling-Perry K, Wang H, Elashoff R, Gales B, Jüppner H, Salusky IB.

J Clin Endocrinol Metab. 2014 Oct;99(10):E1951-6. doi: 10.1210/jc.2014-2125. Epub 2014 Jul 25.

37.

The accuracy of a continuous volumetric balancing system in pediatric continuous renal replacement therapy.

Hanudel MR, Salusky IB, Zaritsky JJ.

Int J Artif Organs. 2014 Mar;37(3):215-21. doi: 10.5301/ijao.5000296. Epub 2014 Apr 4.

38.

FGF23 protein expression in coronary arteries is associated with impaired kidney function.

van Venrooij NA, Pereira RC, Tintut Y, Fishbein MC, Tumber N, Demer LL, Salusky IB, Wesseling-Perry K.

Nephrol Dial Transplant. 2014 Aug;29(8):1525-32. doi: 10.1093/ndt/gft523. Epub 2014 Jan 23.

39.

Disordered FGF23 and mineral metabolism in children with CKD.

Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, Schwartz GJ, Furth SL, Warady BA, Salusky IB.

Clin J Am Soc Nephrol. 2014 Feb;9(2):344-53. doi: 10.2215/CJN.05840513. Epub 2013 Dec 5.

40.

Suppression of iron-regulatory hepcidin by vitamin D.

Bacchetta J, Zaritsky JJ, Sea JL, Chun RF, Lisse TS, Zavala K, Nayak A, Wesseling-Perry K, Westerman M, Hollis BW, Salusky IB, Hewison M.

J Am Soc Nephrol. 2014 Mar;25(3):564-72. doi: 10.1681/ASN.2013040355. Epub 2013 Nov 7.

41.

Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysis.

Zaritsky J, Rastogi A, Fischmann G, Yan J, Kleinman K, Chow G, Gales B, Salusky IB, Wesseling-Perry K.

Nephrol Dial Transplant. 2014 Feb;29(2):437-41. doi: 10.1093/ndt/gft382. Epub 2013 Sep 5.

42.

FGF23 and mineral metabolism in the early post-renal transplantation period.

Wesseling-Perry K, Pereira RC, Tsai E, Ettenger R, Jüppner H, Salusky IB.

Pediatr Nephrol. 2013 Nov;28(11):2207-15. doi: 10.1007/s00467-013-2547-z. Epub 2013 Jul 15.

43.

The skeletal consequences of growth hormone therapy in dialyzed children: a randomized trial.

Bacchetta J, Wesseling-Perry K, Kuizon B, Pereira RC, Gales B, Wang HJ, Elashoff R, Salusky IB.

Clin J Am Soc Nephrol. 2013 May;8(5):824-32. doi: 10.2215/CJN.00330112. Epub 2013 Apr 4.

44.

Chronic kidney disease: mineral and bone disorder in children.

Wesseling-Perry K, Salusky IB.

Semin Nephrol. 2013 Mar;33(2):169-79. doi: 10.1016/j.semnephrol.2012.12.017. Review.

45.

Idiopathic juvenile osteoporosis: a cross-sectional single-centre experience with bone histomorphometry and quantitative computed tomography.

Bacchetta J, Wesseling-Perry K, Gilsanz V, Gales B, Pereira RC, Salusky IB.

Pediatr Rheumatol Online J. 2013 Feb 19;11:6. doi: 10.1186/1546-0096-11-6. eCollection 2013.

46.

Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.

Wesseling-Perry K, Salusky IB.

Pediatr Nephrol. 2013 Apr;28(4):617-25. doi: 10.1007/s00467-012-2381-8. Epub 2013 Feb 5. Review.

47.

Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity?

Bacchetta J, Salusky IB, Hewison M.

Pediatr Nephrol. 2013 Apr;28(4):577-82. doi: 10.1007/s00467-012-2336-0. Epub 2012 Nov 2. Review.

48.

Nutritional vitamin D use in chronic kidney disease: a survey of pediatric nephrologists.

Griffin LM, Denburg MR, Shults J, Furth SL, Salusky IB, Hwang W, Leonard MB.

Pediatr Nephrol. 2013 Feb;28(2):265-75. doi: 10.1007/s00467-012-2307-5. Epub 2012 Oct 20.

49.

Association of pre-kidney transplant markers of mineral and bone disorder with post-transplant outcomes.

Molnar MZ, Kovesdy CP, Mucsi I, Salusky IB, Kalantar-Zadeh K.

Clin J Am Soc Nephrol. 2012 Nov;7(11):1859-71. doi: 10.2215/CJN.01910212. Epub 2012 Sep 6.

50.

Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes.

Bacchetta J, Sea JL, Chun RF, Lisse TS, Wesseling-Perry K, Gales B, Adams JS, Salusky IB, Hewison M.

J Bone Miner Res. 2013 Jan;28(1):46-55. doi: 10.1002/jbmr.1740.

Supplemental Content

Loading ...
Support Center